Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acidic oligopeptide-DOTA-177Lu conjugate
- Development stage
- Preclinical
- Lead developer
- Purdue University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
acidic oligopeptide-DOTA-177Lu conjugate is a preclinical hydroxyapatite-targeted radioligand therapy designed for the treatment of bone metastases. Developed by researchers at Purdue University, the conjugate consists of an acidic oligopeptide ligand that selectively targets exposed hydroxyapatite in both osteolytic and osteoblastic bone lesions, tethered via a stable linker to a DOTA-chelated therapeutic radionuclide, lutetium-177 (177Lu). By homing specifically to exposed hydroxyapatite—which is normally occluded by a cartilaginous sheath in healthy bone—the therapy delivers localized beta radiation to destroy bone metastases while sparing healthy tissues and bone marrow.
- Other names
- 177Lu-labeled acidic oligopeptide conjugateacidic oligopeptide-DOTA-177Lubone cancer-targeted radiotherapyhydroxyapatite-targeted radioligand therapy
02
Targets
DNA
Beyond the preview
Go deeper on acidic oligopeptide-DOTA-177Lu conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acidic oligopeptide-DOTA-177Lu conjugate.